MX2009011387A - Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos. - Google Patents

Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.

Info

Publication number
MX2009011387A
MX2009011387A MX2009011387A MX2009011387A MX2009011387A MX 2009011387 A MX2009011387 A MX 2009011387A MX 2009011387 A MX2009011387 A MX 2009011387A MX 2009011387 A MX2009011387 A MX 2009011387A MX 2009011387 A MX2009011387 A MX 2009011387A
Authority
MX
Mexico
Prior art keywords
sgc
treatment
benign prostate
urological disorders
combinations
Prior art date
Application number
MX2009011387A
Other languages
English (en)
Inventor
Johannes-Peter Stasch
Peter Sandner
Hanna Tinel
Dieter Neuser
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009011387A publication Critical patent/MX2009011387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona composiciones farmacológicas que comprenden un estimulante o activador de la guanilato ciclasa soluble (GCs), solo o en combinación con un inhibidor de la PDE5, para el tratamiento de trastornos urológicos, que comprenden síndrome prostático benigno (SPB), hiperplasia prostática benigna (HPB), aumento benigno de tamaño de la próstata (BPE), obstrucción infravesical (OIV), síntomas del tracto urinario inferior (STUI), trastornos genitourinarios que comprenden síndrome vesical neurogénico (SVN) y (CI), incontinencia urinaria (IU), incontinencia mixta, por urgencia, por estrés o por rebosamiento (MUI, UUI, SUI, OUI) y dolor pélvico (DP).
MX2009011387A 2007-05-12 2008-04-29 Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos. MX2009011387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07009557 2007-05-12
PCT/EP2008/003450 WO2008138483A1 (en) 2007-05-12 2008-04-29 sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS

Publications (1)

Publication Number Publication Date
MX2009011387A true MX2009011387A (es) 2009-11-09

Family

ID=39624195

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011387A MX2009011387A (es) 2007-05-12 2008-04-29 Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.

Country Status (9)

Country Link
US (1) US20100210643A1 (es)
EP (1) EP2144605A1 (es)
AU (1) AU2008250643A1 (es)
BR (1) BRPI0811581A2 (es)
CA (1) CA2686906A1 (es)
IL (1) IL201509A0 (es)
MX (1) MX2009011387A (es)
RU (1) RU2009145935A (es)
WO (1) WO2008138483A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
BRPI1006869A2 (pt) * 2009-01-17 2016-03-15 Bayer Schering Pharma Ag estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
WO2011056511A2 (en) 2009-10-26 2011-05-12 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2011095553A1 (en) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
MX342944B (es) * 2010-02-05 2016-10-18 Adverio Pharma Gmbh Estimuladores de la sgc o activadores de la sgc solos y en combinacion con inhibidores de la pde5 para el tratamiento de la fribrosis quistica.
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
EP2687210A1 (de) * 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
WO2012122340A1 (en) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2766360B1 (en) 2011-08-12 2017-07-12 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
HUE046996T2 (hu) 2012-09-07 2020-04-28 Boehringer Ingelheim Int Alkoxi-pirazolilok, mint oldható guanilát cikláz inhibitorok
WO2015011086A1 (en) 2013-07-25 2015-01-29 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2015089182A1 (en) * 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN106459017B (zh) 2014-07-22 2020-07-17 勃林格殷格翰国际有限公司 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050059660A1 (en) * 2003-08-01 2005-03-17 Pharmacia & Upjohn Company Novel combination
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
WO2006126081A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합

Also Published As

Publication number Publication date
BRPI0811581A2 (pt) 2014-12-09
CA2686906A1 (en) 2008-11-20
WO2008138483A1 (en) 2008-11-20
IL201509A0 (en) 2010-05-31
RU2009145935A (ru) 2011-06-20
US20100210643A1 (en) 2010-08-19
AU2008250643A1 (en) 2008-11-20
EP2144605A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
MX2009011387A (es) Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
WO2008019139A3 (en) Inhibitors of pyruvate kinase and methods of treating disease
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
GB2467090A (en) Degradable whipstock apparatus and methods of use
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
WO2006127431A3 (en) Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
MX2009013725A (es) Composiciones de fragmentos de tejido para el tratamiento de la incontinencia.
AU308201S (en) Spout and mixer tap
AU308202S (en) Mixer tap and spout
AU308199S (en) Mixer tap and spout
MX2009004695A (es) Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un agonista ht1a, en el tratamiento de disfuncion sexual.
WO2008060363A3 (en) Tumor associated markers in the diagnosis of prostate cancer
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008089236A3 (en) Compositions and methods for diagnosing, treating, and preventing prostate conditions
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract
UY29816A1 (es) Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urológicos
MX2012000315A (es) Composicion para el tratamiento de hiperplasia prostatica benigna.
IL198465A0 (en) Triazabenzo[e]azulene derivatives for the treatment of tumors
AU312034S (en) Sprinkler body
AU312033S (en) Sprinkler body
AU313403S (en) Broom body
ATE435246T1 (de) Wässrige behandlungszusammensetzungen und polymere zur verwendung darin
TW200744633A (en) Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors as antiplatelet agents
Parsons et al. Prostate cancer and urinary incontinence
WO2007141661A3 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal